Literature DB >> 26149808

Deletion of Phenylalanine 508 in the First Nucleotide-binding Domain of the Cystic Fibrosis Transmembrane Conductance Regulator Increases Conformational Exchange and Inhibits Dimerization.

P Andrew Chong1, Patrick J Farber1, Robert M Vernon1, Rhea P Hudson1, Anthony K Mittermaier2, Julie D Forman-Kay3.   

Abstract

Deletion of Phe-508 (F508del) in the first nucleotide-binding domain (NBD1) of the cystic fibrosis transmembrane conductance regulator (CFTR) results in destabilization of the domain, intramolecular interactions involving the domain, and the entire channel. The destabilization caused by F508del manifests itself in defective channel processing and channel gating defects. Here, we present NMR studies of the effect of F508del and the I539T stabilizing mutation on NBD1 dynamics, with a view to understanding these changes in stability. Qualitatively, F508del NMR spectra exhibit significantly more peak broadening than WT spectra due to the enhanced intermediate time scale (millisecond to microsecond) motions in the mutant. Unexpectedly, studies of fast (nanosecond to picosecond) motions revealed that F508del NBD1 tumbles more rapidly in solution than WT NBD1. Whereas F508del tumbles at a rate nearly consistent with the monomeric state, the WT protein tumbles significantly more slowly. Paramagnetic relaxation enhancement experiments confirm that NBD1 homodimerizes in solution in the expected head-to-tail orientation. NMR spectra of WT NBD1 reveal significant concentration-dependent chemical shift perturbations consistent with NBD1 dimerization. Chemical shift analysis suggests that the more rapid tumbling of F508del is the result of an impaired ability to dimerize. Based on previously published crystal structures and NMR spectra of various NBD1 mutants, we propose that deletion of Phe-508 affects Q-loop conformational sampling in a manner that inhibits dimerization. These results provide a potential mechanism for inhibition of channel opening by F508del and support the dimer interface as a target for cystic fibrosis therapeutics.
© 2015 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  ABC transporter; F508del; NBD dimerization; cystic fibrosis transmembrane conductance regulator (CFTR); dynamics; nuclear magnetic resonance (NMR); nucleotide-binding domain (NBD); protein processing; protein/protein interaction

Mesh:

Substances:

Year:  2015        PMID: 26149808      PMCID: PMC4645629          DOI: 10.1074/jbc.M115.641134

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  60 in total

1.  Domain interdependence in the biosynthetic assembly of CFTR.

Authors:  Liying Cui; Luba Aleksandrov; Xiu-Bao Chang; Yue-Xian Hou; Lihua He; Tamas Hegedus; Martina Gentzsch; Andrei Aleksandrov; William E Balch; John R Riordan
Journal:  J Mol Biol       Date:  2006-11-10       Impact factor: 5.469

2.  Altered chloride ion channel kinetics associated with the delta F508 cystic fibrosis mutation.

Authors:  W Dalemans; P Barbry; G Champigny; S Jallat; K Dott; D Dreyer; R G Crystal; A Pavirani; J P Lecocq; M Lazdunski
Journal:  Nature       Date:  1991 Dec 19-26       Impact factor: 49.962

3.  Chloride conductance expressed by delta F508 and other mutant CFTRs in Xenopus oocytes.

Authors:  M L Drumm; D J Wilkinson; L S Smit; R T Worrell; T V Strong; R A Frizzell; D C Dawson; F S Collins
Journal:  Science       Date:  1991-12-20       Impact factor: 47.728

4.  NMRPipe: a multidimensional spectral processing system based on UNIX pipes.

Authors:  F Delaglio; S Grzesiek; G W Vuister; G Zhu; J Pfeifer; A Bax
Journal:  J Biomol NMR       Date:  1995-11       Impact factor: 2.835

5.  Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA.

Authors:  J R Riordan; J M Rommens; B Kerem; N Alon; R Rozmahel; Z Grzelczak; J Zielenski; S Lok; N Plavsic; J L Chou
Journal:  Science       Date:  1989-09-08       Impact factor: 47.728

6.  The First Nucleotide Binding Domain of Cystic Fibrosis Transmembrane Conductance Regulator Is a Site of Stable Nucleotide Interaction, whereas the Second Is a Site of Rapid Turnover.

Authors:  Luba Aleksandrov; Andrei A Aleksandrov; Xiu-Bao Chang; John R Riordan
Journal:  J Biol Chem       Date:  2002-02-22       Impact factor: 5.157

7.  Structures of a minimal human CFTR first nucleotide-binding domain as a monomer, head-to-tail homodimer, and pathogenic mutant.

Authors:  Shane Atwell; Christie G Brouillette; Kris Conners; Spencer Emtage; Tarun Gheyi; William B Guggino; Jorg Hendle; John F Hunt; Hal A Lewis; Frances Lu; Irina I Protasevich; Logan A Rodgers; Rich Romero; Stephen R Wasserman; Patricia C Weber; Diana Wetmore; Feiyu F Zhang; Xun Zhao
Journal:  Protein Eng Des Sel       Date:  2010-02-11       Impact factor: 1.650

8.  Spectral density function mapping using 15N relaxation data exclusively.

Authors:  N A Farrow; O Zhang; A Szabo; D A Torchia; L E Kay
Journal:  J Biomol NMR       Date:  1995-09       Impact factor: 2.835

9.  Conserved allosteric hot spots in the transmembrane domains of cystic fibrosis transmembrane conductance regulator (CFTR) channels and multidrug resistance protein (MRP) pumps.

Authors:  Shipeng Wei; Bryan C Roessler; Sylvain Chauvet; Jingyu Guo; John L Hartman; Kevin L Kirk
Journal:  J Biol Chem       Date:  2014-05-29       Impact factor: 5.157

10.  Backbone dynamics of a free and phosphopeptide-complexed Src homology 2 domain studied by 15N NMR relaxation.

Authors:  N A Farrow; R Muhandiram; A U Singer; S M Pascal; C M Kay; G Gish; S E Shoelson; T Pawson; J D Forman-Kay; L E Kay
Journal:  Biochemistry       Date:  1994-05-17       Impact factor: 3.162

View more
  8 in total

1.  Stabilization of a nucleotide-binding domain of the cystic fibrosis transmembrane conductance regulator yields insight into disease-causing mutations.

Authors:  Robert M Vernon; P Andrew Chong; Hong Lin; Zhengrong Yang; Qingxian Zhou; Andrei A Aleksandrov; Jennifer E Dawson; John R Riordan; Christie G Brouillette; Patrick H Thibodeau; Julie D Forman-Kay
Journal:  J Biol Chem       Date:  2017-06-27       Impact factor: 5.157

Review 2.  Molecular modelling and molecular dynamics of CFTR.

Authors:  Isabelle Callebaut; Brice Hoffmann; Pierre Lehn; Jean-Paul Mornon
Journal:  Cell Mol Life Sci       Date:  2016-10-07       Impact factor: 9.261

Review 3.  Molecular mechanisms of cystic fibrosis - how mutations lead to misfunction and guide therapy.

Authors:  Carlos M Farinha; Isabelle Callebaut
Journal:  Biosci Rep       Date:  2022-07-29       Impact factor: 3.976

4.  Targeting the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Protein for the Treatment of Cystic Fibrosis.

Authors:  Ahmed F Abdel-Magid
Journal:  ACS Med Chem Lett       Date:  2016-07-12       Impact factor: 4.345

5.  Binding screen for cystic fibrosis transmembrane conductance regulator correctors finds new chemical matter and yields insights into cystic fibrosis therapeutic strategy.

Authors:  Justin D Hall; Hong Wang; Laura J Byrnes; Suman Shanker; Kelong Wang; Ivan V Efremov; P Andrew Chong; Julie D Forman-Kay; Ann E Aulabaugh
Journal:  Protein Sci       Date:  2016-01-12       Impact factor: 6.725

6.  Speeding Up the Identification of Cystic Fibrosis Transmembrane Conductance Regulator-Targeted Drugs: An Approach Based on Bioinformatics Strategies and Surface Plasmon Resonance.

Authors:  Marco Rusnati; Davide Sala; Alessandro Orro; Antonella Bugatti; Gabriele Trombetti; Elena Cichero; Chiara Urbinati; Margherita Di Somma; Enrico Millo; Luis J V Galietta; Luciano Milanesi; Paola Fossa; Pasqualina D'Ursi
Journal:  Molecules       Date:  2018-01-08       Impact factor: 4.411

7.  Molecular dynamics simulation study on the structural instability of the most common cystic fibrosis-associated mutant ΔF508-CFTR.

Authors:  Mitsuhiko Odera; Tadaomi Furuta; Yoshiro Sohma; Minoru Sakurai
Journal:  Biophys Physicobiol       Date:  2018-02-06

8.  Heterozygous Cystic Fibrosis Transmembrane Regulator Gene Missense Variants Are Associated With Worse Cardiac Function in Patients With Duchenne Muscular Dystrophy.

Authors:  Xuan Jiang; Yanqiu Shao; Faris G Araj; Alpesh A Amin; Benjamin M Greenberg; Mark H Drazner; Chao Xing; Pradeep P A Mammen
Journal:  J Am Heart Assoc       Date:  2020-10-02       Impact factor: 5.501

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.